<DOC>
	<DOCNO>NCT00064701</DOCNO>
	<brief_summary>The purpose study compare safety efficacy tacrolimus/mycophenolate mofetil ( MMF ) , cyclosporine/MMF tacrolimus modify release/MMF de novo kidney transplant recipient .</brief_summary>
	<brief_title>Comparative Study Modified Release ( MR ) Tacrolimus/Mycophenolate Mofetil ( MMF ) de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description>This 3 arm randomize , open-label , comparative , multi-center study de novo kidney transplant recipients 60 center U.S. , Canada Brazil . The study consist 1-year post-transplant efficacy safety study clinical continuation phase minimum 2 year commercial availability tacrolimus modify release , unless Data Safety Monitoring Board sponsor specify otherwise .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Recipient primary retransplanted nonhuman leukocyte antigen ( HLA ) identical living nonHLAidentical cadaveric kidney transplant Age great equal 12 year Recipient donor know seropositive human immunodeficiency virus ( HIV ) Has current malignancy history malignancy Has significant liver disease Has uncontrolled concomitant infection unstable medical condition Is receive everolimus enteric coat mycophenolic acid time study Received kidney cold ischemia time equal 36 hour Received kidney transplant cadaveric donor equal 60 year age Received intravenous immunoglobulin ( IVIG ) therapy prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>De Novo Kidney Transplant</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>PrografÂ®</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>tacrolimus</keyword>
</DOC>